In Reply Funck-Brentano raises several questions regarding our analysis of the association between baseline low-density lipoprotein cholesterol (LDL-C) level and the percentage LDL-C reduction with different lipid-lowering therapies.¹ He notes that for a given percentage reduction, the absolute reduction will vary depending on the baseline level. This mathematical truism misses the point. It has been commonly assumed that percentage LDL-C reduction is constant across baseline LDL-C values for a given dose of a given lipid-lowering therapy. In fact, we demonstrate that PCSK9 inhibition results in a greater percentage LDL-C reduction in patients with lower baseline LDL-C levels.

在回复中， Funk-Brentano 提出了一些关于我们对基线低密度脂蛋白胆固醇 (LDL-C) 水平与不同降脂疗法降低 LDL-C 百分比之间关联的分析的问题。 ¹他指出，对于给定的减少百分比，绝对减少量将根据基线水平而变化。这个数学真理没有抓住要点。人们普遍认为，对于给定降脂治疗的给定剂量，LDL-C 降低百分比在基线 LDL-C 值上是恒定的。事实上，我们证明 PCSK9 抑制可导致基线 LDL-C 水平较低的患者的 LDL-C 降低百分比更大。